作者
Mike Sathekge, Frank Bruchertseifer, Otto Knoesen, Florette Reyneke, Ismaheel Lawal, Thabo Lengana, Cindy Davis, Johncy Mahapane, Ceceila Corbett, Mariza Vorster, Alfred Morgenstern
发表日期
2019/1
期刊
European journal of nuclear medicine and molecular imaging
卷号
46
页码范围
129-138
出版商
Springer Berlin Heidelberg
简介
Background
A remarkable therapeutic efficacy has been demonstrated with 225Ac-prostate-specific membrane antigen (PSMA)-617 in heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) patients. We report our experience with 225Ac-PSMA-617 therapy in chemotherapy-naïve patients with advanced metastatic prostate carcinoma.
Methods
Seventeen patients with advanced prostate cancer were selected for treatment with 225Ac-PSMA-617 in 2-month intervals, with initial activity of 8 MBq, then de-escalation to 7 MBq, 6 MBq or 4 MBq in cases of good response. In one patient, activity was escalated to 13 MBq in the third cycle. Fourteen patients had three treatment cycles administered, while in three patients treatment was discontinued after two cycles due to good response. Six out of 17 patients received additional treatments …
学术搜索中的文章
M Sathekge, F Bruchertseifer, O Knoesen, F Reyneke… - European journal of nuclear medicine and molecular …, 2019